People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Inozyme Pharma, Inc. | — | Pharmaceuticals | Series C | $116.2M | $2.4B | 2018 |
Sarah Bhagat at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sarah Bhagat on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Edward Mathers | 1 | 12 |
| Axel Bolte | 1 | 6 |
| Rob Hopfner | 1 | 6 |
| Martin Edwards | 1 | 5 |
| Lynne Sullivan | 1 | 3 |
| Joseph Schlessinger | 1 | 2 |
| DOUGLAS TRECO | 1 | 2 |
| Reinaldo Diaz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.